No Data
No Data
Coherus BioSciences Completes Acquisition of Surface Oncology
Coherus BioSciences (CHRS) said Friday it has completed the acquisition of Surface Oncology (SURF). Upon closing, Coherus issued 0.1960 of its common shares at $5.2831 apiece for every Surface common
Coherus Completes Surface Oncology Acquisition
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc. (Surface or Surface Oncology), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
Surface Oncology Says Takeover by Coherus BioSciences Gets Backing From ISS, Glass Lewis
Surface Oncology (SURF) said independent proxy advisors Institutional Shareholder Services and Glass Lewis recommended stockholders vote in favor of the buyout by Coherus BioSciences (CHRS). If Surfac
Surface Oncology Announces ISS And Glass Lewis Both Recommend Stockholders Vote "FOR" The Proposed Merger With Coherus BioSciences >SURF
Surface Oncology Announces ISS And Glass Lewis Both Recommend Stockholders Vote "FOR" The Proposed Merger With Coherus BioSciences >SURF
Surface Oncology GAAP EPS of -$0.46
Surface Oncology Q2 EPS $(0.46) Misses $(0.34) Estimate
Surface Oncology (NASDAQ:SURF) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.34) by 35.29 percent. This is unchanged from the same period last year.
No Data